TY - JOUR
T1 - LONG-TERM TREATMENT WITH POTASSIUM CITRATE AND RENAL STONES IN MEDULLARY SPONGE KIDNEY.
AU - Fabris, Antonia
AU - Lupo, Antonio
AU - Bernich, Patrizia
AU - Abaterusso, Cataldo
AU - Marchionna, Nicola
AU - Nouvenne, Antonio
AU - Gambaro, Giovanni
PY - 2010
Y1 - 2010
N2 - BACKGROUND AND OBJECTIVES: Medullary sponge kidney (MSK) is a renal malformation typically associated with nephrocalcinosis and recurrent calcium stones. Incomplete distal renal tubular acidosis, hypocitraturia, and hypercalciuria are common. For stone prevention, patients with MSK generally receive the standard "stone clinic" recommendations and often receive potassium citrate (KC). However, the effect on stone recurrence of citrate treatment in these patients has never been studied.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The issue was retrospectively analyzed on an outpatient basis in 97 patients with a radiologic diagnosis of MSK: 65 had at least one stone risk factor (SRF; hypercalciuria, hypocitraturia, hyperuricosuria, hyperoxaluria) and received KC [29 +/- 8 (SD) mEq/d]; 10 patients with SRF and 22 without received only general stone clinic suggestions. Follow-up was 78 +/- 13, 72 +/- 15, and 83 +/- 14 months, respectively. The 24-hour urinary excretion of calcium, oxalate, uric acid, citrate, and morning urine pH were investigated at baseline and at the end of follow-up.
RESULTS: Parallel to a significant rise in urinary citrate and decreased urinary calcium (all P < 0.001), KC led to a dramatic reduction in the stone event rate (from 0.58 to 0.10 stones/yr per patient). The existence of a group of patients with MSK, those without SRF, with a very low stone rate and no SRF was recognized.
CONCLUSIONS: Treatment with KC is effective in preventing renal stones in the typical patient with MSK. It seems that two clinical phenotypes among patients showing typical MSK features during radiologic study exist.
AB - BACKGROUND AND OBJECTIVES: Medullary sponge kidney (MSK) is a renal malformation typically associated with nephrocalcinosis and recurrent calcium stones. Incomplete distal renal tubular acidosis, hypocitraturia, and hypercalciuria are common. For stone prevention, patients with MSK generally receive the standard "stone clinic" recommendations and often receive potassium citrate (KC). However, the effect on stone recurrence of citrate treatment in these patients has never been studied.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The issue was retrospectively analyzed on an outpatient basis in 97 patients with a radiologic diagnosis of MSK: 65 had at least one stone risk factor (SRF; hypercalciuria, hypocitraturia, hyperuricosuria, hyperoxaluria) and received KC [29 +/- 8 (SD) mEq/d]; 10 patients with SRF and 22 without received only general stone clinic suggestions. Follow-up was 78 +/- 13, 72 +/- 15, and 83 +/- 14 months, respectively. The 24-hour urinary excretion of calcium, oxalate, uric acid, citrate, and morning urine pH were investigated at baseline and at the end of follow-up.
RESULTS: Parallel to a significant rise in urinary citrate and decreased urinary calcium (all P < 0.001), KC led to a dramatic reduction in the stone event rate (from 0.58 to 0.10 stones/yr per patient). The existence of a group of patients with MSK, those without SRF, with a very low stone rate and no SRF was recognized.
CONCLUSIONS: Treatment with KC is effective in preventing renal stones in the typical patient with MSK. It seems that two clinical phenotypes among patients showing typical MSK features during radiologic study exist.
KW - MSK
KW - MSK
UR - http://hdl.handle.net/10807/8960
U2 - 10.2215/CJN.00220110
DO - 10.2215/CJN.00220110
M3 - Article
SN - 1555-9041
VL - 5
SP - 1663
EP - 1668
JO - CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
JF - CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
ER -